Physician profile
Paul Huston Dillahunt
NPI 1184680985
$5,434.96
in general payments reported to CMS, 2019-2025
32 companies · $18.82 in 2025
The $18.82 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $629 · 2021: $1,172 · 2022: $876 · 2023: $1,044 · 2024: $1,238 · 2025: $18.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.94 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $487.93 | 2019-2024 | |
| Pfizer INC. | $484.17 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $480.35 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $416.72 | 2019-2023 | Xarelto |
| Amgen INC. | $303.37 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $291.61 | 2019-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $278.51 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $212.24 | 2020-2021 | |
| Abbott Laboratories | $205.42 | 2020-2022 | |
| Edwards Lifesciences Corporation | $202.23 | 2022 | |
| Cvrx, INC. | $171.16 | 2023-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $157.41 | 2020-2024 | Wainua, Farxiga |
| Esperion Therapeutics, INC. | $156.53 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $152.51 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $145.68 | 2021-2024 | |
| Ge Healthcare | $102.32 | 2019-2020 | |
| Medtronic Vascular, INC. | $101.17 | 2020 | |
| Boston Scientific Corporation | $91.80 | 2021-2024 | Bionic Navigator, Watchman Access System |
| Irhythm Technologies, INC. | $84.05 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Biotronik INC. | $75.79 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $46.89 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $32.98 | 2023-2024 | Inpefa |
| Abiomed | $27.70 | 2024 | Impella |
| Arbor Pharmaceuticals, INC. | $27.30 | 2021 | |
| Atricure, INC. | $23.49 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.33 | 2024 | Arcalyst |
| Philips North America LLC | $19.72 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.19 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $15.94 | 2021 | |
| Baxter Healthcare | $14.65 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dillahunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.